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Adverse events associated with exchange transfusion
and etiology of severe hyperbilirubinemia in near-term and
term newborns
Ali BÜLBÜL, Feride Füsun OKAN, Emel KABAKOĞLU ÜNSÜR, Asiye NUHOĞLU

Aim: To assess clinical features, etiology, and complications in term and near-term newborns who received exchange
transfusion.
Materials and methods: Infants with ≥35 gestational weeks admitted to our neonatal intensive care unit in the first 30
days of life and underwent exchange transfusion due to severe hyperbilirubinemia between 2002 and 2008 were included.
Clinical features, etiology of hyperbilirubinemia, and complications of exchange transfusion were assessed.
Results: Exchange transfusion was performed 86 times in a total of 73 patients. Eleven patients received exchange
transfusion twice, and 1 patient 3 times. A great proportion of the patients (61.6%) were male, and mean (± standard
deviation) gestational age and birth weight of the patients were 38.0 (1.4) weeks and 3249 (619) g, respectively. While the
admission, mean total serum bilirubin levels were 27.5 (7.4) mg/dL. Hemolytic disease was found in 56.1% of the
newborns (n = 41). The most common causes of hemolysis were ABO incompatibility (23.2%) and Rh sensitization
(12.3%). The underlying cause was not able to be identified in 29 (39.7%) cases. The most common 2 complications were
hypocalcemia (n = 7) and thrombocytopenia (n = 5).
Conclusion: This study implies that no etiology was defined in nearly half of the term and near term newborns who
received exchange transfusion. Despite technological advances in neonatal care units in the last decade, the blood
exchange-related complication rates remained the same.
Key words: Hyperbilirubinemia, exchange transfusion, newborn

Kan değişimi uygulanan yenidoğanlarda ciddi hiperbilirubineminin nedenleri ve
kan değişimi uygulamasının yan etkileri
Amaç: Ciddi hiperbilirubinemi nedeniyle kan değişimi uygulanan term ve sınırda term bebeklerde, klinik özelliklerin,
hiperbilirubinemi nedenlerinin ve kan değişimi uygulaması sonucu saptanan yan etkilerin değerlendirilmesi.
Yöntem ve gereç: 2002-2008 yılları içerisinde yaşamın ilk 30 gününde, ciddi hiperbilirubinemi nedeniyle kan değişimi
uygulanan, gebelik haftası ≥35 olan bebekler çalışmaya alındı. Hastaların klinik özellikleri, hiperbilirubinemi nedenleri
ve kan değişiminin yan etkileri incelendi.
Bulgular: Bu dönemde on bir hastaya 2 kez, bir hastaya 3 kez olmak üzere 73 hastaya toplam 86 kez kan değişimi yapıldı.
Hastaların % 61,6’sı erkek, ortalama gebelik haftası 38,0 ± 1,4 hafta ve doğum ağırlığı 3249 ± 619 g olarak saptandı. Yatış
esnasında ortalama serum bilirubin değeri 27,5 ± 7,4 mg/dL idi. Bebeklerin % 56,1’inde (n = 41) hemoliz saptandı. En
sık saptanan hemoliz nedenleri ABO uyuşmazlığı (% 23,2) ve Rh Uyuşmazlığı (% 12,3) idi. Yirmi dokuz hastada (% 39,7)
hiperbilirubineminin nedeni saptanamadı. Kan değişiminin en sık saptanan iki yan etkisi hipokalsemi (n = 7) ve
trombositopeni (n = 5) idi.
Sonuç: Çalışmamızda kan değişimi uygulanan bebeklerin yarısında ciddi hiperbilirubineminin nedeninin saptanamadığı
ve son 10 yılda yenidoğan ünitelerindeki gelişmelere rağmen kan değişimi ile ilgili yan etkilerin değişmediği belirlendi.
Anahtar sözcükler: Hiperbilirubinemi, kan değişimi, yenidoğan
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Introduction
The bilirubin level at which exchange transfusion
(ET) is indicated remains controversial (1,2). This is
because it is very difficult to define the risk of bilirubin
encephalopathy in various categories of the patients,
such as patients with or without hemolysis, term or
premature, or even healthy or ill. Kernicterus has
become uncommon due to the advantage of effective
prevention from rhesus (Rh) incompatibility and the
treatment of elevated bilirubin levels with
phototherapy (3-6). Most reported kernicterus patients
in the world are from the United States (27%),
Singapore (19%), and Turkey (16%) (4). Considering
the high frequency of kernicterus in Turkey, it is clear
that further studies concentrating on the etiology and
treatment outcomes of neonatal jaundice are necessary
and important.
Intensive phototherapy and ET are the main
treatment methods in prevention from kernicterus
(2,4). Though ET is effective, the method can give rise
to numerous complications including transient
hypocalcemia, hypoglycemia, hyponatremia and
thrombocytopenia, rare life threatening infections,
catheter break off, renovascular hypertension,
thrombosis and embolism, and even death (4,7,8). In
this study we aimed to assess the clinical features,
etiology, and complications in term and near-term
newborns who received exchange transfusion because
of severe hyperbilirubinemia, which is one of the most
important neonatal health problems in Turkey.
Materials and methods
Patients
The subjects were newborns with ≥35 gestational
weeks admitted in the first 30 days of life with severe
hyperbilirubinemia to the neonatal intensive care unit
of Şişli Children’s Hospital and received ET between
2002 and 2008. Decision of ET was made according to
the guidelines proposed by the American Academy of
Pediatrics (AAP) (2,9). Files of all patients who
received ET, except partial ET, were reviewed
retrospectively, and 116 patients were determined.
Demographic features, physical examination
findings, nutrition types (breast milk only, formula,
and mixed), birth of place, the age of the newborns
when jaundice was noticed, the age on the first
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admission, the period between admission and ET, and
duration of hospitalization were recorded.
Exchange transfusion procedure and monitoring
complications
According to the standard protocol of ET at our
unit, all the patients were given intensive phototherapy
and enteral nutrition followed till ET process. Gastric
contents were drained via orogastric catheter just
before ET. The procedure was performed in using a
single line (umbilical vein), and the umbilical catheter
was withdrawn soon after the ET ended. No calcium
supplementation was given during the procedure. The
newborns were followed up in terms of heart rate,
respiratory rate, peripheral oxygen saturations, and
blood pressure by means of a cardio-pulmonary
monitoring during at least 8 h after the procedure.
All the blood products used for exchange
transfusion were obtained from the Şişli Children’s
Hospital Blood Center. The blood products withdrawn
from volunteer donors were anticoagulated with citrate
phosphate dextrose adenosine-1 and were <5 days old.
Whole blood ABO compatible between the baby and
mother were used. The double volume ET was
completed in about 1.5-2 h by repeatedly removing and
replacing small aliquots of the blood (<5 mL/kg)
according to our protocol.
An adverse event was defined as any complication
occurring within 1 week after ET (10). The following
definitions were used; hypoglycemia (serum glucose
<45 mg/dL), hypocalcemia (total serum calcium <8
mg/dL), hyponatremia (serum sodium <135 mEq/L),
hyperkalemia (serum potassium >5.5 mEq/L),
thrombocytopenia (platelets below 50,000/mL),
bradycardia detected during and 2 h after ET (heart
rate dropping to <100 beats per min), apnea (cessation
of respirations for >20 s), seizure (any tonic and/or
clonic movement), bacteremia (detected colonization
in the culture taken after ET), and necrotizing
enterocolitis defined according to Bell’s criteria (11).
The records of adverse events, possibly related to ET,
were classified according categories as defined by
Jackson: asymptomatic untreated, asymptomatic
treated, serious transient, serious prolonged,
permanent serious sequel, and dead (8).
Etiologic investigations
According to our ET protocol, following etiologic
investigations were performed in all the newborns at
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baseline: mother-baby blood type, complete blood
count, total and direct serum bilirubin, peripheral
blood smear, reticulocyte count, direct Coombs’ test,
thyroid hormone levels, blood culture before ET, and
serum levels of calcium, sodium, potassium and
glucose.
Conditions with a minimum of 2 following findings
were defined as hemolysis: reticulocyte count >7%,
positive direct Coombs’ test, hematocrit level <45%,
spherocytosis in peripheral blood smear, and increase
in total serum bilirubin level >0.5 mg/dL per hour. The
cause of hemolytic jaundice reported in the records was
classified in the following way: “Rh sensitization” was
defined as jaundice in Rh-positive newborns who were
born to Rh-negative mothers and evidence of
hemolysis. ABO disease was defined as jaundice in
newborns who were born to type O mothers with
positive direct Coombs’ test against the A or B antigens
and evidence of hemolysis. Existence of Kell, C, and E
subgroup incompatibilities were investigated in
patients with hemolysis and without any previously
mentioned hemolytic conditions according to our ET
protocol.
All the newborns with hyperbilirubinemia, the
etiology of which was not able to be clarified by the
above mentioned analyses, were analyzed before ET for
serum levels of glucose-6-phosphate dehydrogenase
(G6PD) and pyruvate kinase, tandem mass
spectrometry (MS) and “TORCH”; and for urinalysis,
culture and reducing substances. Abdominal
ultrasonography was performed to eliminate
hematoma in subjects without hemolysis. Blood and/or
urine culture positivity were assessed as proven sepsis
or urinary tract infection.
Statistics
The demographic features of the study were
assessed via descriptive statistical analyses. Values were
presented as mean ± standard deviation (range).
Results
During the study period, there were 6192 neonatal
intensive care unit admissions, 782 of which were
jaundiced, and 116 newborns received ET. Of these, 33
newborns had prematurity, and 10 newborns had
deficient data in records, so both groups were excluded.
The remaining 73 newborns, who received 86 ET

procedures, were enrolled in the study. Overall, 11
patient had 2, and one had 3 sessions of ET.
Demographic characteristics of the newborns are
shown in Table 1. Among all the newborns, 67 (91.8%)
were admitted because of hyperbilirubinemia and/or
any other reasons, and 6 (8.2%) were detected to have
significant jaundice when were followed up by the wellbaby nursery.
Table 2 shows the common etiologic factors of the
patients who received ET and the most 2 of which were
Rh sensitization and ABO incompatibility. No etiologic
factor was found in 4 hemolytic patients and 25
nonhemolytic patients. One of the nonhemolytic
patients had a history of a sibling with kernicterus
despite ET. Pathological weight loss (>10% than birth
weight) was detected in 14 of the entire group (19.1%),
only 3 had dehydration alone, without any other risk
factors (Table 2). No thyroid dysfunction or any other
abnormality was detected in Tandem MS, TORCH
analyses,
and
abdominal
ultrasonographic
examinations. Three patients whose urine samples had
reducing substances were negative in further analyses.
Ten patients were given intravenous immunoglobulin
prior to ET for hemolysis and direct Coombs positivity.
Total serum bilirubin levels according to the day on
which ET was performed are given in Table 3. ET was
most often performed between days 3 and 6. The
maximum TSB level before ET was 46 mg/dL.
ET related complications are given in Table 4.
According to Jackson’s classification (8), 2
asymptomatic patients were administered a dose of 75
mg/kg per day intravenous calcium when serum levels
decreased to < 6mg/dL. Hypoglycemia persisted in
another asymptomatic patient’s 2-h follow-up, who was
immediately supported with 6-8 mg/kg per min iv
glucose for 24 h. Two infants were given erythrocyte
suspension soon after ET since their hematocrit levels
decreased below <30%. ET was ended in 2 cases
because of bradycardia, whose heart rates recovered
after oxygen therapy using hood. In these 2 patients,
the second ET was not performed since control TSB
levels were below ET indication levels. One newborn
had apnea responding to positive pressure ventilation.
Two additional patients with agitation and tremor had
hypocalcemia, and thereafter were given intravenous
calcium. Petechial rash due to thrombocytopenia was
detected in a newborn; however, thrombocyte
95
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Table 1. Baseline demographic characteristics.

Number of patients, n
Mean gestational age, weeks
Birth weight, g, range, g
Body weight on admission, g
Gender
Male, n (%)
Female, n (%)
Delivery
Spontaneous vaginal, (%)
Cesarean section, (%)
Birth place
Our hospital, n (%)
Other center, n (%)
Home, n (%)
The day family noticed jaundice, day
Postnatal age at the time of admission, day
Mode of feeding before ET
Breastfeeding, n (%)
Formula, n (%)
Mixed, n (%)
Causes of admission
Jaundice, n (%)
Feeding difficulties, n (%)
Respiratory distress, n (%)
Irritability, n (%)
Excess sleep, n (%)
Admission TSB, mg/dL
TSB before ET, mg/dL
Time between admission and ET, h
Duration of phototherapy, h
Hospitalization duration, day
The rate of readmission for phototherapy, n (%)

Value, mean ± SD

Range

73
38.0 ± 1.4
3249 ± 619
2983 ± 569

35-41
2030-5195
1740-5110

45 (61.6)
28 (38.4)
76.7
23.3
15 (20.5)
51 (69.9)
7 (9.6)
2.9 ± 1.7
4.6 ± 2.3

1-8
1-13

42 (57.5)
8 (11.0)
23 (31.5)
43 (58.9)
12 (16.4)
7 (9.6)
6 (8.2)
5 (6.8)
27.5 ± 7.4
29.4 ± 7.2
2.5 ± 1.4
70.5 ± 33.7
7.9 ± 5.6
5 (6.8)

12-46.5
12.5-46
1-6
24-144
2-24

ET: exchange transfusion, TSB: total serum bilirubin, SD: standard deviation

suspension was not given since no signs of bleeding
were seen, anyhow thrombocyte levels recovered after
24 h. A patient was detected to have bacteremia
because blood culture positivity for methicillinresistant coagulase-negative staphylococci was detected
after ET, and then he was treated with vancomycin for
14 days. An infant was transferred to our unit with
respiratory distress and jaundice, underwent ET and
was supported by mechanical ventilation due to a TSB
level of 26 mg/dL, and Hct 17%. Unfortunately this
patient died at the 6th h on the first day. Etiology for
hemolysis could not be ruled out. Though we consider
that the reason of death was primarily associated with
respiratory distress, ET might have probably
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contributed. Total complication rate was 17.8% (n =
13) when those not requiring treatment were excluded.
On admission, 11 patients had irritability and
excess sleep, and another 12 newborns showed feeding
difficulty. Furthermore, clinical findings of acute
encephalopathy were present in 6 patients. Symptoms
of 3 patients vanished after ET, but the others
manifested signs of kernicterus during their 3 monthfollow-up. Two of the latter were home-born, and
hospitalized on days 7 and 13 with TSB levels of 36.5
mg/dL and 36 mg/dL, respectively. The other one had
G6PD deficiency with a TSB level of 41.4 mg/dL, and
underwent ET twice.
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Table 2. Etiology of hyperbilirubinemia in newborns performed exchange transfusion.
Causes of hyperbilirubinemia

n

%*

with hemolysis
ABO incompatibility
Rh sensitization
ABO incompatibility + Rh sensitization
Other blood antigen sensitization
Proven sepsis
Urinary tract infection
G6PD deficiency
No hemolytic etiology determined
Without hemolysis
Proven sepsis
History of a sibling with ET performed
Severe dehydration
No etiologic factor determined

41
17
9
4
2
1
1
3
4
32
3
1
3
25

56.1
23.2
12.3
5.5
2.7
1.4
1.4
4.1
5.5
43.9
4.1
1.4
4.1
34.3

Total unknown etiology

29

39.7

% ratio is given regarding to total patient number.
G6PD: Glucose-6-phosphate dehydrogenase

Table 3. Day of life when ET was performed and mean total serum bilirubin levels.
Day of life when ET
was performed

N

%

TSB,* mean ± SD (range) mg/dL

Day 1 (0-24 h)
Day 2
Day 3
Day 4
Day 5
Day 6
Day 7
≥8 Days

6
8
11
12
11
10
9
6

8.2
11.0
15.1
16.4
15.1
13.7
12.3
8.2

22.9 ± 4.1 (18.0-26.0)
19.0 ± 8.0 (12.5-34.0)
28.5 ± 5.9 (21.5-38.8)
32.3 ± 5.1 (18.7-38.3)
34.2 ± 4.6 (29.2-40.0)
31.9 ± 6.6 (25.5-46.0)
31.8 ± 2.9 (28.7-36.5)
28.9 ± 7.7 (20.5-37.0)

Total

73

100

29.4 ± 7.2 (12.5-46.0)

* Total serum bilirubin levels when ET was started.
ET: exchange transfusion, TSB: total serum bilirubin, SD: standard deviation

Discussion
ABO incompatibility, Rh sensitization, and G6PD
deficiency were found as reasons for severe
hyperbilirubinemia in this large study carried out in
Turkey, where kernicterus and ET appliances are
common. Forty percent of the patients in the study had
no apparent etiologic reason. The literature search
reveals common reasons for severe jaundices requiring

ET, such as hereditary spherocytosis, urinary tract
infections, hypothyroidia, hemolysis due to blood
subgroup incompatibilities, pyruvate kinase enzyme
deficiency, hemoglobinopathies, subdural hematoma,
and adrenal gland hemorrhage (4,5,8,12-14). In a study
carried out in Canada between 2002 and 2004 in which
Rh sensitization newborns were not included since
follow-up,
most
common
causes
for
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Table 4. Adverse events associated with ET.
n
Asymptomatic untreated
Thrombocytopenia
Hypocalcemia
Hypoglycemia
Asymptomatic treated
Hypocalcemia
Hypoglycemia
Anemia
Serious, transient
Apnea (requiring resuscitation)
Bradycardia
Hypocalcemia
Petechial rash from thrombocytopenia
Serious and prolonged /permanent
Bacteremia
Dead

%
12.3

4
3
2
6.8
2
1
2
8.2
1
2
2
1
1.4
1
1

1.4

hyperbilirubinemia in 258 babies were ABO
incompatibility and G6PD deficiency whereas 64% had
no known etiology. ET was performed on these
newborns with a rate of 22.1% (5). Reasons for
hyperbilirubinemia in ET performed term and preterm
infants were reported as follows: Rh sensitization
21.4%-48.1%; ABO incompatibility 19.8%-34%; Rh
sensitization and ABO incompatibility association 4%6.7%; G6PD deficiency 9%-34.4%; prematurity, 5.6%7.4%; subgroup incompatibilities 5.6%; and other
reasons 3.7%-22.2% (4,5,7,8,15-17). We were unable to
find a reason in 40% of the subjects in our study. This
rate was reported previously as 17%-37% (4,7,8,13,14).
It is considered that more novel wider studies
investigating enzymes in bilirubin metabolism like
glucuronyl transferase are required for enlightening the
etiology of these patients, rates of which were reported
to be as high as 40%, whether as in the present study or
previous ones, with the note that the present study has
a privilege to include the maximum number of patients
amongst the studies performed in Eastern Europe and
Middle East Region in the last decade (7,12,15,16).
It is well known that the reasons for
hyperbilirubinemia alter with respect to genetics and
geographical distribution (2). G6PD deficiency is an
important factor in this distribution. Johnson et al.
reported that G6PD deficiency accounted for 31.5% of
98

kernicterus; and the rate is 34.4% for all infants
undergone ET according to Owa et al. (17,18). Eastern
Mediterranean region is said to be the area where
G6PD deficiency is seen common (15). G6PD
deficiency is reported to account for 18% in term
infants undergone ET in south-eastern Turkey (12).
The rate found in this study is 4.1% in ET required
newborns. The city where the study was conducted is
a metropolis with a cosmopolitan structure. Another
study conducted in İstanbul, Turkey was carried out by
Atay et al., and G6PD deficiency was similarly reported
to account for 3.8% of all the term babies admitted for
hyperbilirubinemia (19). Pathological weight loss is a
risk factor for serious hyperbilirubinemia (2,20,21).
This sign indirectly indicates insufficient nutrition and
an increase in enterohepatic bilirubin cycle.
Hyperbilirubinemia development risk is said to
increase whenever the loss gets over 10% according to
AAP (2). Sgro et al. (5) reported that the rate of weight
loss more than 10% accounts for 10.9% as found in
19.1% in our study. This result of ours suggests that
weight loss more than 10% appears as a serious risk
factor for hyperbilirubinemia and ET as well.
It is suggested that if the healthy newborn and early
discharged term and near-term infants with a risk of
jaundice are not on close follow-up, they are readmitted to hospitals for hyperbilirubinemia and they
develop kernicterus more often (22). The
recommendation about this condition is that bilirubin
levels should be assessed before discharge and they
should be followed-up according to the analyses; this
would
provide
early
notice
of
severe
hyperbilirubinemia (23,24).
In this study, only 6 infants with high risk for severe
hyperbilirubinemia developed jaundice while they
stayed at rooming-in, and thus were transferred to the
neonatal unit. The remaining 67 newborns were
admitted to our center from home due to jaundice or
another problem. Furthermore, in this study
approximately 90% of ET performed patients were
born in hospital and the other 10% were born at home.
Although most of the patients were born in
institutional conditions, they all returned back to
hospital with ET requiring bilirubin levels, which
suggest that this is a problem about postpartum followup of term and near-term infants. Two of 3 infants with
kernicterus were born at home and admitted first to
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the hospital between 7 and 13 days, which impedes the
early notice and increases the risk of kernicterus.
Another interesting result of our study is
approximately 40% patients were brought to the
hospital by parents for complaints other than jaundice.
Moreover, infants were brought to our hospital
approximately 2 days after when their families noticed
the jaundice. These results show that inadequate
information about jaundice is given to families. As in
AAP (2) suggestions, families should not only be
verbally informed, but also a detailed
acknowledgement should be made via written
documents contributing to early diagnose, and perhaps
cutting back the need for ET.
Overuse of ET may reduce the incidence of
bilirubin encephalopathy but adverse events remain
common following ET (8,10). Some complications are
as severe as the bilirubin encephalopathy. There are
few recent reports of complications of ET or attempts
to stratify the risk of adverse events based on clinical
condition. Causes of death ascribed to ET include
cardiovascular collapse during the transfusion and the
subsequent complications of necrotizing enterocolitis,
bacterial sepsis, and pulmonary hemorrhage (8).
Mortality rates attributable to ET ranged from 0.65%
to 3.2% in studies performed in the 1960s (25-27), and
from 0.4% to 3.2% during the 1970s and 1980s (2830). Mortality rate of ET in recent years is reported as
0.3%-1.5% (4,7,8,16). One of the 73 patients in this
study (1.3%) died because of complications probably
attributable to ET, similar to previous reports
(4,7,8,16,31). The rate of prolonged/permanent
serious sequel from ET is also very low, approximately
1%, and prior reports indicate that necrotizing
enterocolitis and bacteremia are the most common
severe complications (7,8). Bacteremia was detected
only in 1 infant in the present study due to ET. The
most common serious and transient morbidities
include symptomatic hypocalcemia, hypoglycemia,
bleeding due to thrombocytopenia, catheter-related
complications, apnea, and bradycardia with cyanosis
requiring resuscitation; all were reported as 5.2%-17%
(7,8,31). The rate of serious and transient morbidities
in our study was 8.2%. In a hypocalcemic newborn,

calcium support was not performed during ET
because it was not recommended (32). Similarly, the
protocol in our unit also does not recommend
calcium
support.
Asymptomatic
untreated
complications about laboratory findings were
detected after ET, and recovered within 24-72 h
without any treatment (8,33). In previous studies,
thrombocytopenia, hypoglycemia, and hypocalcemia
were commonly reported (8,10,33). The
asymptomatic untreated complications in our study
were in concordance with the literature. Most of the
complications of ET are usually transient and mild
and recovery is expected along with appropriate care
and follow-up. Notwithstanding apnea, bradycardia
and cyanosis can develop rarely, therefore cardiorespiratory and oxygen saturation monitoring appears
to be indicated. Since many of the complications of
ET are probably unavoidable, the best way to reduce
complications is to prevent the need for ET (8). A
close follow-up for discharged infants (2,4), early
diagnose of infants with high risk before discharge
(23,24), prevention from weight loss via appropriate
nutrition selection (2,5), and intensive phototherapy
appliance in convenient time (18) can greatly reduce
the need for ET.
Conclusions
In conclusion, hyperbilirubinemia continues to
hold the potential threat of complications for bilirubin
encephalopathy and kernicterus apparently in healthy
term and near-term newborn infants. This study shows
that there was no etiologic reason in almost half of the
infants requiring ET. Thus, it suggests that there is a
risk for severe hyperbilirubinemia requiring ET in
healthy term and near-term infants; and also healthy
ones without any risk should be followed-up for
jaundice as well as the newborns with high risk.
Despite technological advances in neonatal care unit
in the last decade, the blood exchange related
complication rates remained the same. Though ET
appears to prevent from bilirubin encephalopathy and
kernicterus, the complications of ET, follow-up of these
patients should be considered with this regard.
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